After more than two years of regulatory struggles, Orexigen Therapeutics Inc. and marketing partner Takeda Pharmaceutical Co. Ltd. have finally gained clearance for the obesity treatment Contrave – but at least they have arrived with a label that presents few obstacles.
FDA gave the green light to Contrave (naltrexone/bupropion extended-release) late on Sept. 10, approving the combination drug for the treatment...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?